First publicly available DNA genetic kit for Clinical Endo-Cannabinoid Deficiency is co-developed through joint-collaboration between laboratories
Portland, OR -- (SBWIRE) -- 02/27/2018 -- The Anantlife-Cannalogix joint-collaboration commenced in January 2018 between Anantlife's Dr. Rahul Kushwah and Cannalogix Foundation's Chief Research Officer, J.B. Creel - on behalf of all patients seeking relief from the systemic effects of an imbalanced Endo-Cannabinoid System (ECS). By mid-February, the first-of-many revolutionary breakthroughs to be co-developed by the joint-collaboration had been announced creating the world's first genetic kit measuring a Clinical Endo-Cannabinoid Deficiency (CECD). CECD was originally theorized by Dr. Ethan Russo (1) in his 2004 article and is believed to be responsible for migraine, fibromyalgia, inflammatory bowel disease and other related conditions that effectively and collectively impact over 20% of the U.S. population - not to mention their families. Due to the collaboration, it is just a matter of time before you and your family physician will be capable of obtaining genetic insight leading to preventative care, symptom management and best of all - individual systemic improvement based on genomics technologies. The technology being incubated around the genomics technologies will produce everything from prenatal vitamins to one-a-day, anti-aging supplements and every single health and wellness product in between – all customized to the individual patient based on their decoded DNA analysis.
There are currently an estimated 19,000 – 20,000 individual human protein coding-genes in an individual's sequence - that's down from what was originally predicted to be well over 100,000 and could continue to change as genomic technologies advance. Cannalogix's collaboration with the world's leading Genomics expert on the ECS, Dr. Kushwah has revealed the necessary pathways and gene expressions to identify CECD. Given that ability, the CECD genetic kit will provide both the medical professional and the patient with the tools necessary to start down a corrective path to optimal wellness. Anantlife's and Cannalogix's collaborative efforts will revolutionize the healthcare system and further normalize the use of medical cannabis by educating and empowering medical professionals in correcting the deficiencies that plague our society. These advancements will lead to increased levels of personal individualized care while decreasing the burdens on an already overwhelmed and overburdened healthcare system by subsequently lowering the cost of clinical care, health insurance, hospitalization and prescription drug coverage for millions of already under-funded and disadvantaged families in America. This is the first development in a series of cutting-edge genetic kits and commercialized products that are being released by the incubator – meant to revolutionize healthcare and lower the overall burden of medical expenses on the patient, the healthcare system and the American tax-payers.
Cannalogix's Chief Research Officer – J.B. Creel states - "Today we introduce you to the future of cognitive and wellness optimization. Anantlife and Cannalogix are pleased to announce our joint-collaboration has resulted in a genetic kit that can identify an endocannabinoid deficiency through DNA analysis. Where can we go from this? Only time and our continued efforts will tell. Anantlife's initial "worlds-first" Cannabis Genetic Kit looking into one's predisposition to side-effects and addiction was revolutionary for patients. The further co-development of the CECD Genetic Kit puts medical science one step closer to winning the war on Endo-Cannabinoid Deficiency – potentially allowing the correction of the root causes of fibromyalgia, migraines, inflammatory bowel disease and many more illnesses. Considering the tendency of the foundation to facilitate the change we wish to see in the world, we are excited to have Anantlife on board and look forward to what future co-developments will manifest from our joint collaboration. I would also like to thank Dr. Rahul Kushwah and Anantlife Canada for joining the SRCF- Cannalogix Brain-Trust and helping the CFRI R&D Incubator and its co-developers foster a happy, healthy humanity for all."
The package, known as CECD.SOLUTIONS will be available early Spring 2018 over the internet at http://CECD.SOLUTIONS/ at the consumer price of $1,500.00, and could save patients thousands of dollars over a lifetime and countless hours of trial and error - not to mention eliminating the unnecessary anxiety, undesired psycho-activity and waste of time, energy and cost. Patients on limited income can still access the package through the SRCF, Cannalogix, and other non-profit clinics via scholarships and or low-to-no interest in-house financing (credit, not a factor - backed by project co-developers) with low monthly payments of only $50 until the package is paid off – please see http://CECD.SOLUTIONS/in-house-financing/ for full details. In an effort to increase quality of care, the foundation is integrating all of Anantlife's genetic kits into the intake process, as well as all on-going in-patient and outpatient care. Proceeds from the CECD.SOLUTIONS package will go to SRCF and CFRI projects that either serve Veteran, Disabled, Indigent or Pediatric patients and or further research to continue our collective goal of fostering a happier, healthier humanity – naturally. The CECD.SOLUTIONS package, in addition to the entire line of Anantlife's genetic kits, will be distributed by the Cannalogix International Research and Care (CIRC) Network providers.
Cannalogix plans to distribute the kits to managed care and independent medical professionals, hospitals, and clinics worldwide through global distribution by late 2018. Please visit http://www.cannalogix.org/dna for the latest advancements and updates in Cannalogix's Patient-Centric studies regarding Nutrigenetics, Epigenetics, Immunogenetics, and Targeted Genomics Technologies from the CFRI R&D Incubator.
The CECD.SOLUTIONS package includes; 1.) CECD genetic decoding, by Anantlife Canada; 2.) a companion outline of beneficial strains, phyto-cannabinoids and terpenoids, by Cannalogix – IP Holdings; 3.) an app to track progress with a built in guide of all available resources for medical, nutrigenetic, epigenetic, and immunogenetic experts and specialists that work with the specific condition(s) – including those within the Cannalogix International Research and Care (CIRC) Network, and clinics that work with low income and disadvantaged in complimentary care, by Xendance Medical Technologies; 4.) 1 full year membership in the SRCF and email support with access to a care coordinator in case the patient might need a referral to a specialist, by SRCFCANNALOGIX, and 5.) access to low-to-no interest financing, by Bluebird & Blacksheep so the test is accessible to all. As an extension of the SRCF-Cannalogix family of organizations - following its commitment to inclusion and diversity without barriers, the CECD.SOLUTIONS package will be made affordable for all patients, regardless of income, location, or circumstance. We encourage all patients to take advantage of the opportunity and obtain disease risk genetic kits as well the gender-specific health and wellness kits to gain a better insight into their overall wellness and being.
For a limited time, Cannalogix and the SRCF are offering FREE 1 YEAR MEMBERSHIPS to anyone who purchases a DNA kit through the http://www.cannalogix.org/dna/ portal and contributes to the build of the ever-evolving database in this transition. The foundation will not share your DNA information/medical records with anyone outside of the incubator for any reason.
The Stormy Ray Cardholders' Foundation (SRCF) is an Oregon 501(c)3 public-charity organization dedicated to medical cannabis advocacy, education, research, and reform – founded 1995 - recognized 1997 – we have served Veteran, disabled and indigent patients since inception. The SRCF is well known as a strategic and disruptive innovator, starting with the passage of Oregon's Measure 67 in 1998 creating the Oregon Medical Marijuana Act (OMMA) through voter initiative. The OMMA was created to serve suffering patients and has subsequently improved over 100,000 lives in Oregon since being voted in. In 2005, the SRCF was the first medical cannabis advocacy organization to unify; judicial, law enforcement, and health officials with the legislature to expand protections and possession limits for patients registered in the Oregon Medical Marijuana Program (OMMP). In 2014, various Directors from the SRCF Board of Directors founded Cannalogix Foundation as a Research and Development Incubator and in 2017 the SRCF re-acquired and consolidated research and development with the Cannalogix Foundation Research Institute and international R&D Incubator. Today the Research Institute and Incubator continue to coordinate and collaborate research on medical cannabis and its efficacy in the treatment and alleviation of over 50 separate illnesses, conditions and cancer. Patients are never turned away due to the lack of ability to pay and patient-wellness remains to be the bottom line in the day to day advancement of Phyto-pharmacological and genomics science. As a 501(c)3 public charity, the SRCF remains a leader in disruptive and strategic innovation contributing to the advancement of; public policy creation and education; law enforcement awareness and training; medical cannabis research and education; titration and delivery protocol development, targeted disease/condition profiling, and personalized patient therapeutics and protocol therapies; and nutrigenetics, epigenetics and immunogenetics research just to name a few.
Media Contact: Kris McAlister email@example.com
Technical Contact: J.B. Creel, EVP - firstname.lastname@example.org
Toll-free: 844-CANNALOGIX (844-226-6256) x707
For more information about Anantlife Canada visit: http://www.anantlife.com
For more information about Cannalogix Foundation visit: http://www.cannalogix.org
For more information about the Stormy Ray Cardholders Foundation visit: http://www.stormyray.org.
Citings: (1) https://www.ncbi.nlm.nih.gov/pubmed/15159679